



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)

A61K 38/43 (2006.01)

(21) International Application Number:

PCT/US2021/051641

(22) International Filing Date:

23 September 2021 (23.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/082,888 24 September 2020 (24.09.2020) US

(71) Applicant: **MERCK SHARP & DOHME CORP.**
[US/US]; 126 EAST LINCOLN AVENUE, RAHWAY,
New Jersey 07065-0907 (US).

(72) Inventors; and

(71) Applicants (for US only): **KRISHNAMACHARI, Yogita**
[US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US). **MITTAL, Sachin** [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US).

ing Hill Road, Kenilworth, New Jersey 07033 (US). **SAN-GANI, Sahil, S.** [US/US]; 1420 Campbell Street, Apt. 101, Rahway, New Jersey 07065 (US). **FORREST, William, P., Jr.** [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US). **SU, Yongchao** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **ZHAO, Xi** [CN/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US).

(74) Common Representative: **MERCK SHARP & DOHME CORP.**; 126 EAST LINCOLN AVENUE, RAHWAY, New Jersey 07065-0907 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND HYALURONIDASE VARIANTS AND FRAGMENTS THEREOF AND METHODS OF USE THEREOF




FIG.9

(57) Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*